AU2003285336B2 - Imidazole-derivatives as factor Xa inhibitors - Google Patents

Imidazole-derivatives as factor Xa inhibitors Download PDF

Info

Publication number
AU2003285336B2
AU2003285336B2 AU2003285336A AU2003285336A AU2003285336B2 AU 2003285336 B2 AU2003285336 B2 AU 2003285336B2 AU 2003285336 A AU2003285336 A AU 2003285336A AU 2003285336 A AU2003285336 A AU 2003285336A AU 2003285336 B2 AU2003285336 B2 AU 2003285336B2
Authority
AU
Australia
Prior art keywords
chloro
imidazole
ylmethyl
isopropyl
thiophen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003285336A
Other languages
English (en)
Other versions
AU2003285336A1 (en
Inventor
Armin Bauer
Hans Matter
Marc Nazare
Herman Schreuder
Michael Wagner
Volkmar Wehner
David William Will
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02027120A external-priority patent/EP1426364A1/en
Priority claimed from EP03011307A external-priority patent/EP1479674A1/en
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2003285336A1 publication Critical patent/AU2003285336A1/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request for Assignment Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Application granted granted Critical
Publication of AU2003285336B2 publication Critical patent/AU2003285336B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003285336A 2002-12-04 2003-11-20 Imidazole-derivatives as factor Xa inhibitors Ceased AU2003285336B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02027120.1 2002-12-04
EP02027120A EP1426364A1 (en) 2002-12-04 2002-12-04 Imidazole-derivatives as factor Xa inhibitors
EP03011307.0 2003-05-19
EP03011307A EP1479674A1 (en) 2003-05-19 2003-05-19 Imidiazole-derivatives as factor xa inhibitors
PCT/EP2003/012996 WO2004050636A2 (en) 2002-12-04 2003-11-20 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (2)

Publication Number Publication Date
AU2003285336A1 AU2003285336A1 (en) 2004-06-23
AU2003285336B2 true AU2003285336B2 (en) 2009-11-26

Family

ID=32471891

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003285336A Ceased AU2003285336B2 (en) 2002-12-04 2003-11-20 Imidazole-derivatives as factor Xa inhibitors

Country Status (12)

Country Link
EP (1) EP1569927B1 (enExample)
JP (1) JP4504820B2 (enExample)
AR (1) AR042261A1 (enExample)
AT (1) ATE401322T1 (enExample)
AU (1) AU2003285336B2 (enExample)
BR (1) BR0317003A (enExample)
CA (1) CA2507624A1 (enExample)
DE (1) DE60322254D1 (enExample)
MX (1) MXPA05005498A (enExample)
PE (1) PE20040700A1 (enExample)
TW (1) TW200504027A (enExample)
WO (1) WO2004050636A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CN101087609B (zh) 2004-10-26 2012-11-14 詹森药业有限公司 因子Xa化合物
TWI427077B (zh) 2004-12-30 2014-02-21 Astex Therapeutics Ltd 吡唑化合物及其用途和含有彼之藥學組成物
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
JP5523829B2 (ja) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2257546B1 (en) 2008-02-21 2012-08-15 Merck Sharp & Dohme Corp. Functionally selective alpha2c adrenoreceptor agonists
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
CN114105881B (zh) * 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors

Also Published As

Publication number Publication date
WO2004050636A2 (en) 2004-06-17
ATE401322T1 (de) 2008-08-15
PE20040700A1 (es) 2004-11-25
WO2004050636A3 (en) 2004-10-14
CA2507624A1 (en) 2004-06-17
BR0317003A (pt) 2005-10-25
DE60322254D1 (de) 2008-08-28
TW200504027A (en) 2005-02-01
EP1569927B1 (en) 2008-07-16
AU2003285336A1 (en) 2004-06-23
MXPA05005498A (es) 2005-07-25
AR042261A1 (es) 2005-06-15
JP2006514093A (ja) 2006-04-27
EP1569927A2 (en) 2005-09-07
JP4504820B2 (ja) 2010-07-14

Similar Documents

Publication Publication Date Title
US7910606B2 (en) Pyrazole-derivatives as factor Xa inhibitors
JP4585448B2 (ja) 第Xa因子阻害剤としてのピラゾール−誘導体
US7365088B2 (en) Indazole-derivatives as factor Xa inhibitors
US7465806B2 (en) Pyrrole-derivatives as factor Xa inhibitors
US20050009827A1 (en) Triazole-derivatives as factor Xa inhibitors
AU2003285336B2 (en) Imidazole-derivatives as factor Xa inhibitors
US7741341B2 (en) Benzimidazole-derivatives as factor Xa inhibitors
AU2004238498B2 (en) Triazole-derivatives as factor Xa inhibitors
US7358268B2 (en) Imidazole derivatives as factor Xa inhibitors
JP4658940B2 (ja) 第Xa因子阻害剤としてのベンゾイミダゾール誘導体
AU2004238500B2 (en) Azaindole-derivatives as factor Xa inhibitors
EP1479678A1 (en) Pyrazole-derivatives as factor xa inhibitors
EP1479674A1 (en) Imidiazole-derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH

Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired